We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-11.51%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$101M
AUM Growth
-$17.5M
Cap. Flow
-$4.67M
Cap. Flow %
-4.63%
Top 10 Hldgs %
44.39%
Holding
99
New
23
Increased
11
Reduced
26
Closed
11

Top Buys

Rank Stock Value
1
ADVM
Adverum Biotechnologies
ADVM
+$1.8M
2
EPIX
ESSA Pharma
EPIX
+$1.59M
3
NEOS
Neos Therapeutics, Inc
NEOS
+$1.4M
4
WINT
Windtree Therapeutics Inc
WINT
+$1.28M
5
ABEO icon
Abeona Therapeutics
ABEO
+$965K

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$2.03M
2
EVFM
Evofem Biosciences, Inc. Common Stock
EVFM
+$1.66M
3
ATRC icon
AtriCure
ATRC
+$1.52M
4
DERM
Dermira, Inc.
DERM
+$832K
5
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 84.13%
2 Miscellaneous 15.67%
3 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
1
AtriCure
ATRC
$2.47B
$10.7M 10.61%
487,946
-60,665
-11% -$1.52M
ABBV icon
2
AbbVie
ABBV
$451B
$6.34M 6.29%
116,581
– –
NXTM
3
DELISTED
NxStage Medical Inc.
NXTM
$5.78M 5.74%
366,554
– –
ZSPH
4
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$4.35M 4.31%
66,194
-906
-1% -$54.4K
ACHN
5
DELISTED
Achillion Pharmaceuticals
ACHN
$3.32M 3.29%
480,300
– –
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.51B
$2.95M 2.93%
258,642
+36,986
+17% +$494K
AERI
7
DELISTED
Aerie Pharmaceuticals
AERI
$2.94M 2.92%
165,669
+8,827
+6% +$160K
BEAT
8
DELISTED
BioTelemetry, Inc.
BEAT
$2.88M 2.86%
235,645
– –
PODD icon
9
Insulet
PODD
$10.1B
$2.75M 2.73%
106,018
– –
RIGL icon
10
Rigel Pharmaceuticals
RIGL
$868M
$2.74M 2.72%
110,974
– –
WINT
11
DELISTED
Windtree Therapeutics Inc
WINT
$2.25M 2.24%
536,325
+193,834
+57% +$1.28M
AGTC
12
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.07M 2.05%
157,192
– –
OTIC
13
DELISTED
Otonomy, Inc.
OTIC
$1.99M 1.97%
111,466
– –
MASI
14
DELISTED
Masimo
MASI
$1.77M 1.76%
46,010
– –
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.68M 1.67%
356,918
-17,000
-5% -$110K
XNPT
16
DELISTED
XENOPORT, INC.
XNPT
$1.63M 1.62%
470,612
-60,420
-11% -$381K
SGYP
17
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$1.57M 1.56%
296,563
-21,000
-7% -$163K
EPIX
18
DELISTED
ESSA Pharma
EPIX
$1.42M 1.41%
+11,425
New +$1.59M
PLX icon
19
Protalix BioTherapeutics
PLX
$205M
$1.41M 1.4%
119,319
-3,760
-3% -$59.8K
CYTR
20
DELISTED
CytRx Corp
CYTR
$1.38M 1.37%
97,169
+47,033
+94% +$797K
TVRD
21
Tvardi Therapeutics
TVRD
$24.3M
$1.34M 1.33%
2,599
-928
-26% -$621K
NEOS
22
DELISTED
Neos Therapeutics, Inc
NEOS
$1.33M 1.32%
+63,400
New +$1.4M
STXS icon
23
Stereotaxis
STXS
$145M
$1.27M 1.26%
1,372,862
-343,216
-20% -$340K
CYAD
24
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$1.26M 1.25%
30,000
– –
ADVM
25
DELISTED
Adverum Biotechnologies
ADVM
$1.16M 1.15%
+14,060
New +$1.8M
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, DAFNA Capital Management held 99 positions worth $101M, down 15% from $118M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

DAFNA Capital Management withdrew a net $4.67M in Q3 2015, closing 11 positions and reducing 26 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $2.03M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, DAFNA Capital Management opened a new position in Adverum Biotechnologies worth $1.16M.

  • DAFNA Capital Management's largest Q3 2015 buy was Adverum Biotechnologies: 14,060 shares worth $1.16M.
  • DAFNA Capital Management added most to Windtree Therapeutics Inc in Q3 2015, an estimated $1.28M increase.
  • DAFNA Capital Management's biggest Q3 2015 reduction was AtriCure, cutting an estimated $1.52M.
  • DAFNA Capital Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $2.03M.
  • DAFNA Capital Management's ten largest holdings make up 44% of its $101M portfolio in Q3 2015.
  • DAFNA Capital Management opened 23 new positions and closed 11 in Q3 2015.
  • DAFNA Capital Management's portfolio value fell 15% quarter-over-quarter to $101M.

Based on DAFNA Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.